Healthcare Providers and Services
Company Overview of The General Hospital Corporation
The General Hospital Corporation operates as a general hospital in Boston. It offers services in the areas of allergy and immunology, blood, cancer, circulatory, dermatology, digestive, heart, infectious diseases, kidneys, lung, obstetrics and gynecology, psychiatry, rheumatology, surgery, and urology; bones, muscles, and joints; brain, spine, and nervous system; endocrine, diabetes, and metabolism; and mouth, teeth, and face. The company also provides patient and family support services, such as billing and insurance, child care, emotional and support programs, executive health, international patient, medical interpreter, medical records, mind body medicine, nursing, nutrition, patient and ...
55 Fruit Street
Boston, MA 02114
Founded in 1811
Key Executives for The General Hospital Corporation
Chief of Dermatology Service, Director of Melanoma Program for Mgh Cancer Center and Director of Cutaneous Biology Research Center
Chairman of the Chiefs' Council
Chief of Molecular Biology
Compensation as of Fiscal Year 2016.
The General Hospital Corporation Key Developments
The General Hospital Corporation Presents at 2016 World Alliance Forum in San Francisco, Nov-21-2016 03:55 PM
Oct 27 16
The General Hospital Corporation Presents at 2016 World Alliance Forum in San Francisco, Nov-21-2016 03:55 PM. Venue: The Golden Gate Club, San Francisco, California, United States. Speakers: David Milan, Assistant Physician.
Editas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital
Aug 3 16
Editas Medicine Inc. entered into an exclusive license agreement with Massachusetts General Hospital (MGH) to access intellectual property and technology related to high-fidelity Cas9 nucleases and Cas9 PAM variants that will enable the Company to address an expanded range of genetically-defined diseases with the potential for enhanced specificity.
Abpro Announces Agreements with Massachusetts General Hospital and Brigham and Women's Hospital to Co-Develop Therapeutics for Inflammation, Autoimmunity, Fibrosis, Oncology
May 19 16
Abpro announced co-development agreements with Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH). By leveraging Abpro's DiversImmune platform, Abpro will co-develop multiple monoclonal antibodies with MGH for use in its oncology and inflammation and autoimmunity research programs and with BWH for its fibrosis research. With MGH, Abpro will collaborate with John H. Stone, MD, MPH, Director of Clinical Rheumatology and Professor of Medicine, Harvard Medical School, and Shiv Pillai, MD, PhD, Associate Geneticist, Center for Cancer Research and Professor of Medicine, Harvard Medical School, for both fibrosis and oncology. With BWH, Abpro will work with Michael B. Brenner, MD, Theodore B. Bayles Professor of Medicine Chief, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, in the areas of inflammation and autoimmunity. In addition to the full development of basic research in areas relevant to rheumatic and allergic diseases, translational research and clinical research at the population level and patient therapeutics, the division has also organized and integrated much of its research to provide interdisciplinary progress in several key human diseases. According to these co-development agreements, MGH and BWH will work with Abpro towards the development of new therapeutic antibodies using Abpro's Diversimmune platform, which is designed to generate antibodies with high sensitivity and specificity for advancing human health.
Similar Private Companies By Industry
Recent Private Companies Transactions